Omics-based insights into therapy failure of pediatric B-lineage acute lymphoblastic leukemia
- PMID: 31565196
- PMCID: PMC6747058
- DOI: 10.4081/oncol.2019.435
Omics-based insights into therapy failure of pediatric B-lineage acute lymphoblastic leukemia
Abstract
B-lineage acute lymphoblastic leukemia (B-ALL) is the most common type of cancer seen in children and is characterized by a variable clinical course. Although there have been remarkable improvements in the therapy outcomes of pediatric B-ALL, treatment failure remains the leading-cause of death in 18% of the afflicted patients during the first 5 years after diagnosis. Molecular heterogeneities of pediatric B-ALL play important roles as determinants of the therapy response. Therefore, many of these molecular abnormalities have an established prognostic value in the disease. The present review discusses the omics-based revelations from epigenomics, genomics, transcriptomics and proteomics about treatment failure in pediatric B-ALL. Next it highlights the promise of the molecular aberration-targeted therapy to improve the treatment outcomes.
Keywords: Pediatric B-ALL; omics; therapy failure.
©Copyright: the Author(s), 2019.
Conflict of interest statement
Conflict of interest: the author reports no conflicts of interest.
References
-
- Siegel R, Naishadham D, Jemal A. Cancer statistics 2013. CA Cancer J Clin 2013;63:11-30. - PubMed
-
- Alrawaji AI, Alshahrani Z, Alzahrani W, Alomran F, Al-Madouj A. Cancer Incidence Reports (2015), Saudi cancer registries, national health registries, Saudi health council, Riyadh, Saudi Arabia. Available from: https://nhic.gov.sa/eServices/Documents/E%20SCR%20final%206%20NOV.pdf Accessed: May 2019.
-
- Al-Sudairy R, Al-Nasser A, Alsultan A, et al. Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia in Saudi Arabia: A multi-institutional retrospective national collaborative study. Pediatr Blood Cancer 2014;61:74-80. - PubMed
LinkOut - more resources
Full Text Sources
